keyword
MENU ▼
Read by QxMD icon Read
search

Liposomal amphotericine b

keyword
https://www.readbyqxmd.com/read/28820697/case-report-treatment-of-widespread-nodular-post-kala-azar-dermal-leishmaniasis-with-extended-dose-liposomal-amphotericin-b-in-bangladesh-a-series-of-four-cases
#1
Ariful Basher, Shomik Maruf, Proggananda Nath, Md Golam Hasnain, Muhammod Abdul Mukit, Azim Anuwarul, Fatima Aktar, Rupen Nath, Afm Akhtar Hossain, Abul Hasnat Milton, Dinesh Mondal, Abul Khair Mohammad Sumsuzzaman, Ridwanur Rahman, Mohammad Abul Faiz
Post kala-azar dermal leishmaniasis (PKDL) is a skin manifestation which usually appears after visceral leishmaniasis. It is now proved that PKDL patients serve as a reservoir for anthropometric leishmanial transmission. Hence, to achieve the kala-azar elimination target set by the World Health Organization in the Indian Subcontinent, PKDL cases should be given priority. The goal of treatment for PKDL should be early reepithelizlization and rapid cure, but unfortunately this has been difficult to achieve, especially for patients with severe lesions...
August 14, 2017: American Journal of Tropical Medicine and Hygiene
https://www.readbyqxmd.com/read/28820684/lack-of-efficacy-of-liposomal-amphotericin-b-against-acute-and-chronic-trypanosoma-cruzi-infection-in-mice
#2
Karl V Clemons, Raymond A Sobel, Marife Martinez, Rodrigo Correa-Oliveira, David A Stevens
Acute and chronic infection with Trypanosoma cruzi affects millions of people. The current therapeutic options are highly toxic and often not effective. Liposomal amphotericin B (LABORATORY) has been demonstrated previously to have some activity in murine models. In our studies, higher dosages given multiple times were tested for activity against acute or chronic disease, exploring whether intermittent and brief regimens could be effective, as might then prove useful in human, particularly outpatient, therapy...
August 14, 2017: American Journal of Tropical Medicine and Hygiene
https://www.readbyqxmd.com/read/28815733/comparison-of-the-pharmacokinetic-profiles-of-two-different-amphotericin-b-formulations-in-healthy-dogs
#3
B Bingöl, T Bakirel
This study was conducted to compare the pharmacokinetic profiles of conventional (Fungizone(®) ) and liposomal amphotericin B (AmBisome(®) ) formulations in order to predict their therapeutic properties, and evaluate their potential differences in veterinary treatment. For this purpose, twelve healthy mixed breed dogs received both drugs at a dose of 0.6 mg/kg by intravenous infusion over a 4-min period in a total volume of 40 ml. Blood samples were collected at 0, 0.5, 1, 1.5, 2, 3, 4, 8, 12, 24, 48, 72 and 96 hr after dosing, and concentrations of drug in plasma were determined by high-performance liquid chromatography (HPLC)...
August 16, 2017: Journal of Veterinary Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28815602/efficacy-and-safety-of-amphotericin-b-formulations-a-network-meta-analysis-and-a-multicriteria-decision-analysis
#4
Fernanda S Tonin, Laiza M Steimbach, Helena H Borba, Andreia C Sanches, Astrid Wiens, Roberto Pontarolo, Fernando Fernandez-Llimos
OBJECTIVES: Despite its broad spectrum, conventional amphotericin B (AB) is associated with serious adverse events. Lipid-based formulations may offer safer options. We aimed to synthesize the evidence of efficacy and safety of AB formulations. METHODS: We performed a systematic review and network meta-analysis (NMA) to compare all available formulations: conventional AB; lipid complex or ABLC; colloidal dispersion or ABCD; liposomal or LAB; AB in Intralipid. Randomized controlled trials were searched in four databases...
August 17, 2017: Journal of Pharmacy and Pharmacology
https://www.readbyqxmd.com/read/28806478/successful-stepdown-treatment-of-pulmonary-histoplasmosis-with-thrice-weekly-liposomal-amphotericin-b-in-a-hospital-associated-outpatient-infusion-centre-a-case-report
#5
P O Lewis, I Khan, P Patel
WHAT IS KNOWN AND OBJECTIVE: Amphotericin is the preferred treatment for pulmonary histoplasmosis during pregnancy. The long half-life of amphotericin supports less than daily administration. CASE SUMMARY: A 28-year-old pregnant woman diagnosed with recurrent pulmonary histoplasmosis was initiated on liposomal amphotericin 250 mg (4 mg/kg) intravenously daily. After 2 weeks, the patient was discharged and successfully received 250 mg thrice weekly at a hospital-associated outpatient infusion centre...
August 14, 2017: Journal of Clinical Pharmacy and Therapeutics
https://www.readbyqxmd.com/read/28805117/fungal-fatal-attraction-a-mechanistic-review-on-targeting-liposomal-amphotericin-b-ambisome-%C3%A2-to-the-fungal-membrane
#6
Linda Soo Hoo
Liposomal amphotericin B (AmBisome(®)) is a lipid-based nanotherapeutic that is used successfully worldwide to treat a broad range of life-threatening invasive fungal infections. In subtropical regions, AmBisome is emerging as the treatment of choice for human parasitic protozoan pathogens such as those from the genus Leishmania. The key to the remarkable efficacy of AmBisome is attributed to its liposome based formulation to deliver a potent drug at high dosage with significantly reduced toxicity in patients with immunocompromised systems...
August 14, 2017: Journal of Liposome Research
https://www.readbyqxmd.com/read/28774701/fungal-infections-in-hiv-aids
#7
REVIEW
Andrew H Limper, Antoine Adenis, Thuy Le, Thomas S Harrison
Fungi are major contributors to the opportunistic infections that affect patients with HIV/AIDS. Systemic infections are mainly with Pneumocystis jirovecii (pneumocystosis), Cryptococcus neoformans (cryptococcosis), Histoplasma capsulatum (histoplasmosis), and Talaromyces (Penicillium) marneffei (talaromycosis). The incidence of systemic fungal infections has decreased in people with HIV in high-income countries because of the widespread availability of antiretroviral drugs and early testing for HIV. However, in many areas with high HIV prevalence, patients present to care with advanced HIV infection and with a low CD4 cell count or re-present with persistent low CD4 cell counts because of poor adherence, resistance to antiretroviral drugs, or both...
July 31, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/28768499/simultaneous-primary-invasive-cutaneous-aspergillosis-in-two-preterm-twins-case-report-and-review-of-the-literature
#8
Floriane Gallais, Julie Denis, Olfa Koobar, Laurence Dillenseger, Dominique Astruc, Raoul Herbrecht, Ermanno Candolfi, Valérie Letscher-Bru, Marcela Sabou
BACKGROUND: Primary invasive cutaneous aspergillosis is a rare fungal infection that occurs mostly in immunocompromised patients. Newborns of very low birth weight present a high risk for this type of infection due to an immaturity of the cutaneous barrier and of the immune system. CASE PRESENTATION: We describe here a case of simultaneous invasive cutaneous aspergillosis in two preterm twins. Two male preterm bichorionic biamniotic twins (A & B) were born at a general hospital by spontaneous normal delivery at 24 weeks and 6 days of gestation...
August 2, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/28756612/clinical-pharmacokinetics-of-systemically-administered-antileishmanial-drugs
#9
REVIEW
Anke E Kip, Jan H M Schellens, Jos H Beijnen, Thomas P C Dorlo
This review describes the pharmacokinetic properties of the systemically administered antileishmanial drugs pentavalent antimony, paromomycin, pentamidine, miltefosine and amphotericin B (AMB), including their absorption, distribution, metabolism and excretion and potential drug-drug interactions. This overview provides an understanding of their clinical pharmacokinetics, which could assist in rationalising and optimising treatment regimens, especially in combining multiple antileishmanial drugs in an attempt to increase efficacy and shorten treatment duration...
July 29, 2017: Clinical Pharmacokinetics
https://www.readbyqxmd.com/read/28752062/prototheca-a-danger-underwater
#10
Carolina Velez-Mejia, Juan Velez-Londoño
Prototheca wickerhamii rarely causes systemic infection in humans but when it occurs, there are coexisting comorbidities. This case illustrated shows the manifestation of this opportunistic microorganism in an immunosuppressed patient. The patient was successfully treated with Liposomal amphotericin B with complete resolution of the lesions.
2017: IDCases
https://www.readbyqxmd.com/read/28725544/successful-haploidentical-stem-cell-transplantation-with-prophylactic-administration-of-liposomal-amphotericin-b-after-invasive-pulmonary-zygomycosis
#11
Testuro Ochi, Yuta Katayama, Takeshi Okatani, Ryota Imanaka, Kohei Kyo, Mitsuhiro Itagaki, Shinya Katsutani, Koji Iwato, Hideki Asaoku
A 54-year-old woman with acute myeloid leukemia (AML) achieved complete remission by induction chemotherapy, but developed zygomycosis after consolidation therapy. As zygomycosis could not be cured by liposomal amphotericin B and micafungin, left lower lobectomy was performed. As AML relapsed 7 months after onset, she received haploidentical stem cell transplantation under administration of liposomal amphotericin B. Despite experiencing severe acute graft-versus-host disease, she remains alive with no relapse of either zygomycosis or AML...
December 2017: Medical Mycology Case Reports
https://www.readbyqxmd.com/read/28712122/clinical-features-and-treatment-response-of-cutaneous-leishmaniasis-in-north-west-ethiopia
#12
Helina Fikre, Rezika Mohammed, Saba Atinafu, Johan van Griensven, Ermias Diro
OBJECTIVE: Cutaneous leishmaniasis (CL) receives far less attention than visceral leishmaniasis. Nevertheless, CL is predominantly caused by a unique species in Ethiopia (L aethiopica), which is known to cause severe forms such as diffuse (DCL) and mucocutaneous leishmaniasis (MCL). We report on the number and type of CL cases diagnosed, the clinical features, the treatments and treatment outcomes in North-West Ethiopia. METHODS: This is a retrospective chart record analysis of CL patients treated at the Leishmania Research and Treatment Center (LRTC) of the University of Gondar, Ethiopia...
July 16, 2017: Tropical Medicine & International Health: TM & IH
https://www.readbyqxmd.com/read/28698667/phylogenetic-analysis-reveals-two-genotypes-of-the-emerging-fungus-mucor-indicus-an-opportunistic-human-pathogen-in-immunocompromised-patients
#13
Saad J Taj-Aldeen, Muna Almaslamani, Bart Theelen, Teun Boekhout
Mucormycosis is a rare fungal infection caused by Mucor indicus. Phylogenetic analysis of many M. indicus isolates, mainly sampled from different clinical and environmental specimens collected worldwide, revealed two genotypes, I and II, based on ITS and D1/D2 LSU rDNA sequences. A retrospective review of the literature revealed 13 cases. Eight (76.9%) patients had disseminated infections, and the overall mortality rate was 30.7%. A pulmonary infection caused by M. indicus genotype I in a liver transplant recipient was disseminated to include the skin and was successfully treated with liposomal amphotericin B and aggressive surgery...
July 12, 2017: Emerging Microbes & Infections
https://www.readbyqxmd.com/read/28687695/hiding-in-plain-sight-a-case-of-chronic-disseminated-histoplasmosis-with-central-nervous-system-involvement
#14
Guramrinder Singh Thind, Sandeep Patri
A 64-year-old man presented with gradual onset of confusion, ataxia and 25-pound weight loss over 3 months. MRI of the brain revealed two enhancing cerebellar lesions suspicious for metastases. Positron emission tomography-CT showed enhancement of cervical and axillary lymph nodes. Left axillary lymph node biopsy showed no evidence of malignancy but instead showed fungal organisms morphologically consistent with Histoplasma spp. Disseminated histoplasmosis with central nervous system involvement was suspected...
July 6, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/28687071/recurrence-of-visceral-and-muco-cutaneous-leishmaniasis-in-a-patient-under-immunosuppressive-therapy
#15
Gilles Darcis, Gert Van der Auwera, Jean-Baptiste Giot, Marie-Pierre Hayette, Françoise Tassin, Jorge Arrese Estrada, Lieselotte Cnops, Michel Moutschen, Laurence de Leval, Philippe Leonard
BACKGROUND: Leishmaniasis is a protozoan disease caused by parasites of the genus Leishmania, transmitted to humans by sandflies. The diagnosis of leishmaniasis is often challenging as it mimics many other infectious or malignant diseases. The disease can present in three ways: cutaneous, mucocutaneous, or visceral leishmaniasis, which rarely occur together or consecutively. CASE PRESENTATION: The patient was a 52 years old immunosuppressed Belgian woman with a long history of severe rheumatoid arthritis...
July 7, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/28680340/successful-treatment-of-pulmonary-candidiasis-and-aspergillosis-in-patient-with-refractory-hodgkin-lymphoma-using-micafungin-case-study-and-brief-literature-review
#16
Marta Barańska, Renata Kroll-Balcerzak, Lidia Gil, Joanna Rupa-Matysek, Mieczysław Komarnicki
The number of patients with hematological malignancies who develop invasive fungal disease (IFD) has increased dramatically in recent decades. This increase is attributed to impairment of the host immune system due to intensive cytotoxic chemotherapies, use of corticosteroids and profound immunosuppression after hematopoietic stem cell transplantation (HSCT). Additionally, the increasing prevalence of fungal infections caused by emerging and rare pathogens, IFD of mixed etiology or of atypical localization is observed...
2017: Central-European Journal of Immunology
https://www.readbyqxmd.com/read/28674314/candida-tropicalis-biofilm-formation-and-efficacy-of-liposomal-amphotericin-b-using-time-lapse-images
#17
Akira Kawai, Yuka Yamagishi, Hiroshige Mikamo
Candida species bloodstream infection such as candidemia remains a significant with high morbidity and mortality. Bloodstream infections caused by Candida species is often associated with the ability of Candida to form biofilms by using medical devices, such as central venous catheters. Non-albicans Candida species are increasing gradually in recent clinical practices. One of the Candida species, C. tropicalis, is likely to form biofilms and is also an independent risk factor with high morbidity and mortality in hospitalized patients...
July 1, 2017: Japanese Journal of Infectious Diseases
https://www.readbyqxmd.com/read/28673256/cryptococcosis-in-patients-with-hematological-diseases-a-14-year-retrospective-clinical-analysis-in-a-chinese-tertiary-hospital
#18
Rui-Ying Wang, Yan-Qiong Chen, Ji-Qin Wu, Xuan Wang, Ya-Hui Cao, Hua-Zhen Zhao, Li-Ping Zhu
BACKGROUND: Cryptococcal infection has become a public health challenge globally. However, information about cryptococcal infection in patients with hematological diseases remains relatively rare. METHODS: HIV-uninfected cryptococcosis cases with hematological diseases admitted to Huashan Hospital from January 2001 to December 2014 were reviewed. RESULTS: In total, 33 cryptococcosis patients were enrolled, including 12 malignant and 21 non-malignant hematological cases...
July 3, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/28673017/prognostic-factors-for-death-from-visceral-leishmaniasis-in-patients-treated-with-liposomal-amphotericin-b-in-an-endemic-state-in-brazil
#19
Bruna Dias Tourinho, Frederico Figueiredo Amâncio, Marcela Lencine Ferraz, Mariângela Carneiro
Objective: To characterize the clinical and epidemiological profiles of patients with visceral leishmaniasis (VL) treated with liposomal amphotericin B (LAmB) and to identify prognostic factors for death from VL in 2008-2012 in the state of Minas Gerais, Brazil. Methods: A historical cohort study was conducted using data obtained from treatment requests forms, Brazilian Notifiable Disease Information System and the Mortality Information System. Case-fatality rates of patients with VL treated with LAmB were compared with patients treated with other therapies...
April 1, 2017: Transactions of the Royal Society of Tropical Medicine and Hygiene
https://www.readbyqxmd.com/read/28672999/continuous-intrathecal-administration-of-liposomal-amphotericin-b-for-treatment-of-refractory-cryptococcus-neoformans-encephalitis-a-case-report
#20
Haiting Xie, Peng Luo, Zhongli Li, Rui Li, Haitao Sun, Duobin Wu
The aim of the present study was to investigate the treatment of refractory Cryptococcus neoformans encephalitis with continuous administration of liposomal amphotericin B (AmB). Liposomal AmB was administered to a 28-year-old male by intravenous injection, with daily increasing dosages up to 150 mg per day and combined use of fluconazole (0.4 g per day) and oral flucytosine tablets (1.5 g per day). Following 5 months of treatment, C. neoformans could still be detected in the ink stain of cerebrospinal fluid, but the patient could not tolerate a further increase in the dosage of liposomal AmB...
July 2017: Experimental and Therapeutic Medicine
keyword
keyword
81255
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"